Annual report pursuant to Section 13 and 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.6.0.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
May 30, 2014
Sep. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2014
Rental expenses     $ 340,064 $ 305,638 $ 83,556
Shares of stock issued in acquisition 1,194,862        
Number of contingent shares issuable for acquisition 1,493,577        
Cash in acquisition $ 3,500,000        
Value of shares issued in acquisition $ 10,180,224        
Number of shares issued for acquisition 1,194,862        
Lease expiration date     Dec. 31, 2017    
Milestone 3 [Member]          
Number of shares issued for acquisition   995,718      
Description of contingent period  

Contingent upon the approval of an Investigational New Drug Application (“IND”) within three years of the closing date of the SKS acquisition.